DDR1 and neoplasm: These findings align with preclinical studies of DDR1 inhibitory antibodies: ECD-neutralizing antibodies disrupt collagen fiber alignment, mitigate immune exclusion and inhibit tumor growth in immunocompetent hosts (10).